Extendicare Inc. (TSE:EXE – Get Free Report) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as C$10.93 and last traded at C$10.88, with a volume of 24619 shares. The stock had previously closed at C$10.54.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the company. TD Securities boosted their target price on Extendicare from C$9.50 to C$10.50 and gave the company a “hold” rating in a research note on Thursday, November 14th. BMO Capital Markets set a C$11.00 price objective on Extendicare and gave the company a “market perform” rating in a research report on Thursday, January 30th. Finally, Royal Bank of Canada raised their target price on shares of Extendicare from C$9.50 to C$11.00 and gave the stock a “sector perform” rating in a report on Thursday, November 28th.
Check Out Our Latest Stock Analysis on Extendicare
Extendicare Trading Down 1.9 %
Extendicare (TSE:EXE – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported C$0.19 earnings per share for the quarter. Extendicare had a net margin of 4.28% and a return on equity of 60.00%. During the same quarter in the previous year, the business earned $0.13 earnings per share. As a group, sell-side analysts anticipate that Extendicare Inc. will post 0.6134729 EPS for the current year.
Extendicare Announces Dividend
The company also recently announced a monthly dividend, which will be paid on Friday, February 14th. Investors of record on Friday, February 14th will be issued a $0.04 dividend. This represents a $0.48 annualized dividend and a yield of 4.32%. The ex-dividend date of this dividend is Friday, January 31st. Extendicare’s dividend payout ratio is 70.59%.
About Extendicare
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Featured Articles
- Five stocks we like better than Extendicare
- Trading Halts Explained
- Uber’s Business, Cash Flow, and AI are Why it Will Set a New High
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
- Want to Profit on the Downtrend? Downtrends, Explained.
- These are the 3 Stocks Most Likely to Split in 2025
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.